

Adam J Olszewski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5493347/publications.pdf>

Version: 2024-02-01

246
papers

5,831
citations

147726

31
h-index

91828

69
g-index

248
all docs

248
docs citations

248
times ranked

10174
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining and treating high-grade B-cell lymphoma, NOS. <i>Blood</i> , 2022, 140, 943-954.	0.6	19
2	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	0.6	50
3	CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab. <i>Leukemia and Lymphoma</i> , 2022, 63, 31-42.	0.6	5
4	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
5	Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study. <i>Oncologist</i> , 2022, 27, 532-e542.	1.9	3
6	Ferritin, sex, and the wildfire of inflammation in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	0.6	0
7	Functional Status and Survival in Older Nursing Home Residents With Advanced Nonâ€“Small-Cell Lung Cancer: A SEER-Medicare Analysis. <i>JCO Oncology Practice</i> , 2022, , OP2100460.	1.4	3
8	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac037.	0.4	8
9	BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 128-128.	0.8	2
10	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
11	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12
12	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	2.6	12
13	Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3Î²) inhibitor, in refractory adult T-Cell leukemia/lymphoma. <i>Cancer Biology and Therapy</i> , 2022, 23, 417-423.	1.5	7
14	Seroconversion and outcomes after initial and booster <sc>COVID</sc>â€“19 vaccination in adults with hematologic malignancies. <i>Cancer</i> , 2022, 128, 3319-3329.	2.0	27
15	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	0.6	59
16	Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis. <i>Journal of Geriatric Oncology</i> , 2021, 12, 256-261.	0.5	1
17	Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. <i>Oncologist</i> , 2021, 26, 120-132.	1.9	37
18	Early Palliative Care Services and End-of-Life Care in Medicare Beneficiaries with Hematologic Malignancies: A Population-Based Retrospective Cohort Study. <i>Journal of Palliative Medicine</i> , 2021, 24, 63-70.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1120-1124.	0.6	34
20	Outcomes of lenalidomide or bortezomib-based regimens in older patients with plasma cell myeloma. <i>American Journal of Hematology</i> , 2021, 96, 14-22.	2.0	4
21	The Impact of Ground Tire Rubber Oxidation with H ₂ O ₂ and KMnO ₄ on the Structure and Performance of Flexible Polyurethane/Ground Tire Rubber Composite Foams. <i>Materials</i> , 2021, 14, 499.	1.3	23
22	Abstract PS7-57: Patient risk factors for loss to breast oncologic follow up. , 2021, , .		0
23	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	1.7	21
24	Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). <i>American Journal of Hematology</i> , 2021, 96, E123-E126.	2.0	9
25	Structural Changes and Their Implications in Foamed Flexible Polyurethane Composites Filled with Rapeseed Oil-Treated Ground Tire Rubber. <i>Journal of Composites Science</i> , 2021, 5, 90.	1.4	6
26	Characterization of Highly Filled Glass Fiber/Carbon Fiber Polyurethane Composites with the Addition of Bio-Polyol Obtained through Biomass Liquefaction. <i>Materials</i> , 2021, 14, 1391.	1.3	12
27	WhIMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes. <i>American Journal of Hematology</i> , 2021, 96, E218-E222.	2.0	12
28	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
29	International Forum on Walking Blood Bank Programmes: Responses. <i>Vox Sanguinis</i> , 2021, 116, e44-e70.	0.7	0
30	International Forum on Walking Blood Bank Programmes: Summary. <i>Vox Sanguinis</i> , 2021, 116, 924-929.	0.7	2
31	Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 3935-3952.	0.9	7
32	Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 93-101.	1.1	1
33	Prevalence of functional limitations and their associations with systemic cancer therapy among older adults in nursing homes with advanced non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 765-770.	0.5	5
34	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
35	Ground Tire Rubber Filled Flexible Polyurethane Foam Effect of Waste Rubber Treatment on Composite Performance. <i>Materials</i> , 2021, 14, 3807.	1.3	16
36	Synthesis and Physicochemical Characteristics of Chitosan-Based Polyurethane Flexible Foams. <i>Processes</i> , 2021, 9, 1394.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
38	Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. <i>JAMA Oncology</i> , 2021, 7, 1714.	3.4	63
39	Prognostication and Treatment of Burkitt Lymphoma in the Modern Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S16-S18.	0.2	0
40	Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. <i>Blood Advances</i> , 2021, 5, 5525-5535.	2.5	18
41	Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 68-73.	0.6	5
42	Aggressive CD4/CD8 Double-Negative Primary Cutaneous T-Cell Lymphoma With Dural Invasion: A Rare Presentation of Mycosis Fungoides?. <i>American Journal of Dermatopathology</i> , 2021, 43, 63-66.	0.3	0
43	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021, 138, 455-455.	0.6	4
44	A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse. <i>Blood</i> , 2021, 138, 1382-1382.	0.6	2
45	Impact of Early Palliative Care on End-of-Life Outcomes in Hematologic Malignancies. <i>Journal of Palliative Medicine</i> , 2021, , .	0.6	4
46	Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL. <i>Blood</i> , 2021, 138, 650-650.	0.6	9
47	Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies. <i>Blood</i> , 2021, 138, 3511-3511.	0.6	2
48	Functional Status and Therapy for Nursing Home Residents with Diffuse Large B-Cell Lymphoma: A Population-Based Study. <i>Blood</i> , 2021, 138, 1918-1918.	0.6	0
49	A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy. <i>Blood</i> , 2021, 138, 184-184.	0.6	1
50	Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies. <i>Blood</i> , 2021, 138, 302-302.	0.6	16
51	Global Risk Indicator and Therapy for Older Patients With Diffuse Large B-Cell Lymphoma: A Population-Based Study. <i>JCO Oncology Practice</i> , 2021, , OP2100513.	1.4	1
52	Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I (CFI) in Primary Myelofibrosis (PMF). <i>Blood</i> , 2021, 138, 1472-1472.	0.6	2
53	Optimization of Foamed Polyurethane/Ground Tire Rubber Composites Manufacturing. <i>Materials Proceedings</i> , 2021, 7, 12.	0.2	3
54	Thrombosis in COVID-19: A Narrative Review of Current Literature and Inpatient Management. <i>Rhode Island Medical Journal (2013)</i> , 2021, 104, 14-19.	0.2	2

#	ARTICLE	IF	CITATIONS
55	Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 198-201.	0.6	13
56	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	2.0	18
57	Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1055-1062.	3.0	9
58	Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 354-361.	2.0	19
59	What a headache! Double-hit lymphoma with CNS recurrence – Role of chimeric antigen receptor (CAR) T-cell therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 757-762.	0.6	4
60	Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. <i>Thrombosis Research</i> , 2020, 196, 375-378.	0.8	37
61	End-of-life care quality outcomes among Medicare beneficiaries with hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 3606-3614.	2.5	24
62	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
63	Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3360-3368.	0.6	0
64	Fatal Mucormycosis and Aspergillosis in an Atypical Host: What Do We Know about Mixed Invasive Mold Infections?. <i>Case Reports in Infectious Diseases</i> , 2020, 2020, 1-6.	0.2	5
65	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
66	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
67	Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study. <i>Leukemia</i> , 2020, 34, 2794-2797.	3.3	10
68	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
69	Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1784-1796.	0.6	16
70	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
71	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	2.5	29
72	Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 857-860.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Abstract P2-16-19: Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H+BC): A Brown University oncology group (BrUOG) study. , 2020, , .		1
74	Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethylators for Acute Myeloid Leukemia. Blood, 2020, 136, 6-7.	0.6	1
75	CD5 Expression in Marginal Zone Lymphoma (MZL) Predicts Worse Outcomes with Rituximab (R) but Not with Bendamustine/Rituximab (BR). Blood, 2020, 136, 50-51.	0.6	1
76	Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma. Blood, 2020, 136, 21-22.	0.6	5
77	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. Blood, 2020, 136, 27-28.	0.6	9
78	Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 43-45.	0.6	41
79	Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States. Blood, 2020, 136, 6-8.	0.6	3
80	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 37-38.	0.6	37
81	Functional Status and Therapy for Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study. Blood, 2020, 136, 37-38.	0.6	2
82	Whimsical (Waldenstrom's Macroglobulinemia Study Involving CART-wheel): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data. Blood, 2020, 136, 30-31.	0.6	1
83	Abstract 2338: Comparison of genomic alterations in lung cancer specimens from high and low radon zones: Search for a genomic fingerprint. , 2020, , .		0
84	Abstract 172: Molecular predictors of central nervous system (CNS) recurrence in diffuse large B-cell lymphoma (DLBCL). , 2020, , .		0
85	Abstract 733: Clonotypic cell-free DNA(cfDNA) in the cerebrospinal fluid (CSF) of patients with aggressive lymphomas. , 2020, , .		0
86	Role of Neutrophil Lymphocyte Ratio [NLR] As a Biomarker of Frailty and Predictor of Survival Among Older Adults with Multiple Myeloma (MM). Blood, 2020, 136, 6-6.	0.6	2
87	Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study. Blood, 2020, 136, 15-16.	0.6	1
88	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. Blood, 2020, 136, 49-50.	0.6	1
89	Decreased Lymphoma-Specific Mortality in Patients with Splenic Marginal Zone Lymphoma in the United States. Blood, 2020, 136, 9-9.	0.6	0
90	Comparison of End-of-Life Care Quality Outcomes and Indicators of Palliative Needs between Medicare Beneficiaries with Solid and Hematologic Malignancies. Blood, 2020, 136, 11-11.	0.6	0

#	ARTICLE	IF	CITATIONS
91	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020, 136, 46-49.	0.6	0
92	Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record. <i>Rhode Island Medical Journal</i> (2013), 2020, 103, 78-83.	0.2	0
93	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020, 136, 35-36.	0.6	23
94	Radiation therapy in primary testicular lymphoma: does practice match the standard of care?. <i>Leukemia and Lymphoma</i> , 2019, 60, 523-526.	0.6	6
95	Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base. <i>Leukemia and Lymphoma</i> , 2019, 60, 3426-3433.	0.6	8
96	Use of bone-marrow modifying agents and clinical outcomes in older adults with multiple myeloma. <i>Cancer Medicine</i> , 2019, 8, 6945-6954.	1.3	5
97	Prognostic significance of upfront radiation therapy in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E190-E194.	2.0	3
98	Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. <i>Hematology</i> , 2019, 24, 378-386.	0.7	23
99	Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. <i>British Journal of Haematology</i> , 2019, 186, e31-e35.	1.2	17
100	–Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma–. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1085-1094.	1.0	48
101	Comparative effectiveness of lenalidomide, bortezomib, and their combination as first-line treatment of older patients with myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e9.	0.2	0
102	Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. <i>Cancer</i> , 2019, 125, 550-558.	2.0	6
103	Bortezomib plus <sc>EPOCH</sc> is effective as frontline treatment in patients with plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 679-682.	1.2	55
104	Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2019, 134, 2824-2824.	0.6	6
105	Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies. <i>Blood</i> , 2019, 134, 384-384.	0.6	1
106	Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma. <i>Blood</i> , 2019, 134, 3155-3155.	0.6	1
107	Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study. <i>Blood</i> , 2019, 134, 265-265.	0.6	4
108	Evaluating the Incidence of Cardiovascular and Thrombotic Events in Secondary Polycythemia. <i>Blood</i> , 2019, 134, 3511-3511.	0.6	4

#	ARTICLE	IF	CITATIONS
109	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397.	0.6	3
110	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	0.6	9
111	BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 4460-4460.	0.6	1
112	Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA). <i>Blood</i> , 2019, 134, 2854-2854.	0.6	1
113	Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis. <i>Blood</i> , 2019, 134, 1862-1862.	0.6	1
114	Geographic variation in the incidence of marginal zone lymphoma (MZL) subtypes and infectious risk factors.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13094-e13094.	0.8	0
115	Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas. <i>Blood</i> , 2019, 134, 2800-2800.	0.6	1
116	Billed palliative care services and end-of-life care in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 43-43.	0.8	2
117	Geographic Variation in the Incidence of Marginal Zone Lymphoma Subtypes and Infectious Risk Factors in the United States. <i>Blood</i> , 2019, 134, 4012-4012.	0.6	1
118	Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study. <i>Blood</i> , 2019, 134, 3477-3477.	0.6	0
119	Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. <i>Hematology</i> , 2019, 24, 378-386.	0.7	12
120	Overexpression of Tpl2 is linked to imatinib resistance and activation of <sc>MEK</sc> and <sc>ERK</sc> and <sc>NF-κB</sc> pathways in a model of chronic myeloid leukemia. <i>Molecular Oncology</i> , 2018, 12, 630-647.	2.1	35
121	Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2018, 181, 495-504.	1.2	21
122	Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 204-209.	0.2	6
123	Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. <i>American Journal of Hematology</i> , 2018, 93, E1-E3.	2.0	15
124	Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. <i>Leukemia and Lymphoma</i> , 2018, 59, 1375-1383.	0.6	27
125	Use of Charity Financial Assistance for Novel Oral Anticancer Agents. <i>Journal of Oncology Practice</i> , 2018, 14, e221-e228.	2.5	28
126	Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. <i>Journal of Clinical Oncology</i> , 2018, 36, 2879-2886.	0.8	12

#	ARTICLE	IF	CITATIONS
127	Bone marrow-specific loss of ABL1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. <i>Blood</i> , 2018, 132, 2053-2066.	0.6	20
128	Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. <i>Blood</i> , 2018, 132, 717-726.	0.6	71
129	Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. <i>Current Treatment Options in Oncology</i> , 2018, 19, 38.	1.3	92
130	Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia. <i>Blood</i> , 2018, 132, 2442-2442.	0.6	1
131	Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study. <i>Blood</i> , 2018, 132, 709-709.	0.6	1
132	Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. <i>Blood</i> , 2018, 132, 451-451.	0.6	3
133	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. <i>Blood</i> , 2018, 132, 453-453.	0.6	1
134	Radiation therapy in primary testicular lymphoma (PTL): Does practice match the standard of care?. <i>Journal of Clinical Oncology</i> , 2018, 36, 7544-7544.	0.8	1
135	Radium-223 following front-line chemotherapy for patients with non-small cell lung cancer and bone metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21211-e21211.	0.8	1
136	Hospice use among Medicare fee-for-service (FFS) or managed-care organization (MCO) enrollees with leukemia and myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10025-10025.	0.8	0
137	Diagnosis-to-Treatment Interval As a Prognostic Factor in Aggressive T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 2913-2913.	0.6	0
138	Survival and Risk of Central Nervous System Recurrence in Burkitt or High-Grade B-Cell Lymphoma in the DA-EPOCH-R Era. <i>Blood</i> , 2018, 132, 2983-2983.	0.6	1
139	End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies. <i>Blood</i> , 2018, 132, 829-829.	0.6	1
140	Adjuvant Chemotherapy Administration and Survival Outcomes in Lymphoma Survivors with Common Solid Tumors: A Population-Based Study. <i>Blood</i> , 2018, 132, 621-621.	0.6	0
141	Using Machine Learning to Classify the "Goodness" of Hmsc-Derived and AML-Derived EV's. <i>Blood</i> , 2018, 132, 5244-5244.	0.6	0
142	Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations. <i>Blood</i> , 2018, 132, 3841-3841.	0.6	1
143	Prognosis after Upfront Radiation Therapy in Plasma Cell Myeloma: Analysis of the National Cancer Data Base. <i>Blood</i> , 2018, 132, 3230-3230.	0.6	0
144	Loss of Abelson Interactor-1 Is Linked to Inflammatory Hematopoiesis and Accelerated Aging of Hematopoietic System. <i>Blood</i> , 2018, 132, 1285-1285.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia. <i>Stem Cells and Development</i> , 2017, 26, 656-677.	1.1	17
146	Blunt tools, burning questions: using cancer registry data to study relapsed/refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1013-1015.	0.6	0
147	Variation in the use of upâ€front chemotherapy for indolent Bâ€cell lymphomas and chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2017, 35, 921-924.	0.8	0
148	Statistical moments in superposition models and strongly intensive measures. <i>Physical Review C</i> , 2017, 95, .	1.1	7
149	Comparative outcomes of immunochemotherapy regimens in WaldenstrÃ¶m macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 179, 106-115.	1.2	14
150	Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw202.	3.0	47
151	Partial correlation analysis method in ultrarelativistic heavy-ion collisions. <i>Physical Review C</i> , 2017, 96, .	1.1	12
152	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	0.8	132
153	Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3306-3314.	0.8	35
154	Outcomes of secondary cancers among myeloma survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8043-8043.	0.8	1
155	Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study. <i>PLoS ONE</i> , 2017, 12, e0172957.	1.1	27
156	Closure of Medicare Part D coverage gap by the Affordable Care Act (ACA) and use of oral anti-myeloma agents.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6522-6522.	0.8	0
157	Mammography use, incidence, and survival of primary breast lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13087-e13087.	0.8	0
158	Use of hospice services among Medicare beneficiaries with acute and chronic leukemias.. <i>Journal of Clinical Oncology</i> , 2017, 35, 68-68.	0.8	0
159	Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database. <i>Blood Advances</i> , 2016, 1, 112-121.	2.5	28
160	Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. <i>Aids</i> , 2016, 30, 787-796.	1.0	29
161	Human immunodeficiency virusâ€associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 2689-2697.	2.0	43
162	Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1121-1129.	2.3	18

#	ARTICLE	IF	CITATIONS
163	Survival Claims From Observational Data on Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 1425-1427.	0.8	3
164	Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis. <i>Haematologica</i> , 2016, 101, e488-e491.	1.7	9
165	Formulating a novel prognostic index for diffuse large B-cell lymphoma: T cells break the Silence. <i>Leukemia and Lymphoma</i> , 2016, 57, 2733-2735.	0.6	0
166	Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. <i>Oncologist</i> , 2016, 21, 1377-1386.	1.9	36
167	Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute–Designated Cancer Program. <i>Journal of Oncology Practice</i> , 2016, 12, e396-e404.	2.5	12
168	Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis. <i>Leukemia and Lymphoma</i> , 2016, 57, 676-684.	0.6	8
169	Bone Marrow-Specific Loss of AB11 Induces Myelofibrosis through a Mechanism Involving Activation of NF- κ B. <i>Blood</i> , 2016, 128, 1203-1203.	0.6	1
170	Comparative Effectiveness of Rituximab-Based Immunochemotherapy in Waldenstrom's Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2986-2986.	0.6	3
171	CD20-Negative Large B-Cell Lymphomas: Analysis of the National Cancer Data Base. <i>Blood</i> , 2016, 128, 4226-4226.	0.6	3
172	Outcomes of multimodality therapy for gallbladder cancer in the United States (US): Analysis of the National Cancer Data Base (NCDB).. <i>Journal of Clinical Oncology</i> , 2016, 34, 313-313.	0.8	1
173	Therapy and outcomes of primary central nervous system lymphoma (PCSNL) in the United States: Analysis of the National Cancer Data Base (NCDB).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2026-2026.	0.8	0
174	Variation in the administration of early chemotherapy for indolent lymphomas: Analysis of the National Cancer Data Base (NCDB).. <i>Journal of Clinical Oncology</i> , 2016, 34, e18005-e18005.	0.8	0
175	Adjuvant therapy for gallbladder carcinoma (GBCA): Analysis of the National Cancer Data Base (NCDB).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4082-4082.	0.8	0
176	Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era. <i>Blood</i> , 2016, 128, 1994-1994.	0.6	0
177	Association of Medicare Part D Coverage and Low-Income Subsidies with Use of Novel Oral Agents in Multiple Myeloma. <i>Blood</i> , 2016, 128, 686-686.	0.6	28
178	Variation in the Use of Splenectomy for Splenic Lymphomas: Analysis of the National Cancer Data Base. <i>Blood</i> , 2016, 128, 3584-3584.	0.6	0
179	Hydrodynamic modeling of pseudorapidity flow correlations in relativistic heavy-ion collisions and the torque effect. <i>Physical Review C</i> , 2015, 91, .	1.1	17
180	Multibin correlations in a superposition approach to relativistic heavy-ion collisions. <i>Physical Review C</i> , 2015, 92, .	1.1	6

#	ARTICLE	IF	CITATIONS
181	Two-particle correlations in pseudorapidity in a hydrodynamic model. <i>Physical Review C</i> , 2015, 92, .	1.1	15
182	Limits of registry data to understand survival disparities in lymphoma. <i>Lancet Haematology</i> , 2015, 2, e459-e460.	2.2	1
183	Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. <i>Cancer</i> , 2015, 121, 2230-2236.	2.0	33
184	Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2015, 121, 3472-3480.	2.0	11
185	Health Insurance-Related Disparities in Lymphoma Survival Are Partly Mediated by Baseline Clinical Factors. <i>Oncologist</i> , 2015, 20, 1223-1224.	1.9	4
186	Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database. <i>American Journal of Hematology</i> , 2015, 90, 696-701.	2.0	20
187	Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.2	1
188	Treatment Selection and Outcomes in Early-Stage Classical Hodgkin Lymphoma: Analysis of the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2015, 33, 625-633.	0.8	91
189	Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. <i>Cancer Causes and Control</i> , 2015, 26, 1163-1172.	0.8	18
190	Survival of Patients With Neuroendocrine Carcinoma of the Colon and Rectum. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 294-303.	0.7	79
191	Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 942-950.	0.6	14
192	Overall survival and competing risks of death in patients with Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>British Journal of Haematology</i> , 2015, 169, 81-89.	1.2	110
193	Surgical management of metastatic colon cancer: A population-based analysis. <i>Journal of Geriatric Oncology</i> , 2015, 6, 446-453.	0.5	6
194	Watchful Waiting As Initial Management of Advanced-Stage Follicular Lymphoma in the Rituximab Era: Analysis of the National Cancer Data Base. <i>Blood</i> , 2015, 126, 2692-2692.	0.6	2
195	Downregulation of Mir-181a Restores Chemosensitivity to Imatinib Mesylate in Chronic Myeloid Leukemia Cells Resistant to Tyrosine Kinase Inhibitors. <i>Blood</i> , 2015, 126, 4016-4016.	0.6	3
196	Increased Fracture Risk in Patients with Untreated Chronic Lymphocytic Leukemia (CLL): A Population-Based Analysis. <i>Blood</i> , 2015, 126, 878-878.	0.6	3
197	Breast cancer recurrence in older patients with clinically node-negative T1-T2 tumors managed without sentinel node biopsy (SNB) and without adjuvant radiation therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 528-528.	0.8	0
198	Epidemiology and management of HIV-related non-Hodgkin lymphoma (NHL) in the United States (US): Analysis of the National Cancer Data Base (NCDB). <i>Journal of Clinical Oncology</i> , 2015, 33, 1521-1521.	0.8	3

#	ARTICLE	IF	CITATIONS
199	Prognosis of HIV-Associated Hodgkin Lymphoma in the Antiretroviral Therapy Era: Analysis of the National Cancer Data Base (NCDB). <i>Blood</i> , 2015, 126, 3861-3861.	0.6	0
200	Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. <i>American Journal of Cancer Research</i> , 2015, 5, 2229-40.	1.4	9
201	Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study. <i>Leukemia and Lymphoma</i> , 2014, 55, 1570-1577.	0.6	10
202	Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database. <i>American Journal of Hematology</i> , 2014, 89, 310-314.	2.0	120
203	Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis. <i>International Journal of Cancer</i> , 2014, 134, 2961-2971.	2.3	148
204	Chlorambucil-Induced Acute Interstitial Pneumonitis. <i>Case Reports in Hematology</i> , 2014, 2014, 1-5.	0.3	3
205	Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 866-873.	0.4	20
206	Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome. <i>Osteoporosis International</i> , 2014, 25, 1187-1190.	1.3	11
207	Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. <i>Annals of Hematology</i> , 2014, 93, 449-458.	0.8	33
208	Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. <i>Leukemia</i> , 2014, 28, 2165-2177.	3.3	12
209	Lymph node involvement in colon cancer patients decreases with age; a population based analysis. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1474-1480.	0.5	20
210	New abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance. <i>Experimental Hematology</i> , 2014, 42, S31.	0.2	0
211	Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 642-649.	0.4	34
212	Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>Blood</i> , 2014, 123, 3999-4000.	0.6	91
213	Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia. <i>Blood</i> , 2014, 124, 855-855.	0.6	3
214	Nodal involvement and impact of adequate staging in older patients with resectable colon cancer: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 424-424.	0.8	21
215	Chemotherapy or combined modality therapy for early-stage Hodgkin lymphoma: A comparative, population-based study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8546-8546.	0.8	0
216	Survival of high-grade neuroendocrine carcinomas (HGNEC) of the colon and rectum: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3541-3541.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Cellular level of Abelson interactor-1 as a marker predicting chemoresistance.. Journal of Clinical Oncology, 2014, 32, 7107-7107.	0.8	0
218	Race-Specific Features and Treatment Patterns of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) in the United States: Analysis of the National Cancer Data Base. Blood, 2014, 124, 2594-2594.	0.6	0
219	Utility of the International Prognostic Index (IPI), Revised IPI and a Model-Based Score for Risk Stratification of Diffuse Large B-Cell Lymphoma (DLBCL) in the National Cancer Data Base (NCDB). Blood, 2014, 124, 1308-1308.	0.6	0
220	Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. Cancer, 2013, 119, 3672-3679.	2.0	55
221	Phase I Study of Oxaliplatin in Combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leucovorin (G-FLIE) in Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas. Journal of Gastrointestinal Cancer, 2013, 44, 182-189.	0.6	2
222	Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Annals of Hematology, 2013, 92, 567-568.	0.8	21
223	Evaluation of incidental neutropenia in a multi-ethnic setting. International Journal of Laboratory Hematology, 2013, 35, e6-8.	0.7	4
224	Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: Application and outcomes. Breast, 2013, 22, 793-798.	0.9	18
225	Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Research and Treatment, 2013, 138, 215-223.	1.1	25
226	Survival of patients with marginal zone lymphoma. Cancer, 2013, 119, 629-638.	2.0	181
227	Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Annals of Oncology, 2013, 24, 1352-1359.	0.6	29
228	Forward-backward multiplicity correlations in relativistic heavy-ion collisions in a superposition approach. Physical Review C, 2013, 88, .	1.1	10
229	A phase II study of complete neoadjuvant therapy in rectal cancer (CONTRE): The Brown University Oncology Group.. Journal of Clinical Oncology, 2013, 31, 335-335.	0.8	6
230	Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: Analysis of the Surveillance, Epidemiology and End Results (SEER)-Medicare database.. Journal of Clinical Oncology, 2013, 31, 75-75.	0.8	0
231	Melanoma of ocular, mucosal, and genital sites: Epidemiology and survival outcomes.. Journal of Clinical Oncology, 2013, 31, 9051-9051.	0.8	0
232	Evaluation of the physician-patient communication assessment tool (CAT) in a hematology-oncology practice.. Journal of Clinical Oncology, 2013, 31, 14-14.	0.8	1
233	Living In Remission: Disparities In Conditional Survival Among Non-Hodgkin Lymphoma Survivors. Blood, 2013, 122, 2915-2915.	0.6	0
234	Survival After Rituximab-Based Chemoimmunotherapy In Older Patients With Follicular, Nodal Marginal Zone and Small Lymphocytic Lymphoma: Analysis Of SEER-Medicare Data. Blood, 2013, 122, 1736-1736.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. American Journal of Hematology, 2012, 87, E119-E122.	2.0	17
236	Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. International Journal of Hematology, 2012, 95, 311-314.	0.7	11
237	Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma. American Journal of Hematology, 2012, 87, 521-524.	2.0	8
238	Radiotherapy in Stage I and II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT): Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. Blood, 2012, 120, 2053-2053.	0.6	1
239	Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer.. Journal of Clinical Oncology, 2012, 30, 1034-1034.	0.8	12
240	Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.. Journal of Clinical Oncology, 2012, 30, 8045-8045.	0.8	0
241	Vertebral Compression Fractures in Patients with Chronic Lymphocytic Leukemia: Incidence and Risk Factors. Blood, 2012, 120, 4586-4586.	0.6	0
242	Paroxysmal Nocturnal Hemoglobinuria Presenting with a Left Intraventricular Thrombus in a Patient with Prior Thymoma and Aplastic Anemia. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S8442.	0.6	2
243	Empowering Targeted Therapy: Lessons from Rituximab. Science Signaling, 2004, 2004, pe30-pe30.	1.6	25
244	Thrombotic Thrombocytopenic Purpura Associated with Abacavir in a Patient with HIV Infection. Journal of Intensive Care Medicine, 2003, 18, 156-159.	1.3	1
245	Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model. Science, 2000, 288, 335-339.	6.0	680
246	Recycling of Waste Rubber by Thermo-Mechanical Treatment in a Twin-Screw Extruder. , 0, , .		8